<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00635999</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH039172-01</org_study_id>
    <nct_id>NCT00635999</nct_id>
  </id_info>
  <brief_title>A Comparison Between Cognitive, Behavioral, and Cognitive-Behavioral Therapy for Generalized Anxiety Disorder</brief_title>
  <official_title>Desensitization and Cognitive Therapy in General Anxiety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michelle G. Newman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Penn State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of three adaptive coping treatments in lessening
      anxiety in adults with generalized anxiety disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Generalized anxiety disorder (GAD) is a common psychiatric disorder that affects nearly 6.8
      million adults in the United States. GAD is characterized by persistent feelings of worry and
      anxiety that remain even when there is little reason for concern. The excessive worry that
      people with GAD experience can be so extreme that carrying out activities of daily life
      becomes difficult. GAD is often accompanied by physical symptoms as well, including muscle
      aches, nausea, sweating, exhaustion, irritability, frequent urination, and shaking. People
      with GAD are also at a higher risk for other disorders, including depression and substance
      abuse, making early treatment of GAD important. Forms of psychotherapy that concentrate on
      stress management, relaxation techniques, and control of thoughts about anxiety-provoking
      situations may be effective treatments for people with GAD. This study will evaluate the
      effectiveness of three adaptive coping treatments, relaxation and self-control
      desensitization, cognitive behavioral therapy (CBT), and a combination of the two, in
      lessening anxiety in adults with GAD.

      Participation in this study will last about 28 months. All participants will first complete
      three assessment sessions that will include an interview about anxiety symptoms and medical
      history, self-report questionnaires, and a physiological evaluation. After the first
      interview, participants will be asked to rate their level of anxiety four times a day in a
      diary. They will continue with these daily diary entries through the completion of treatment.
      Once participants complete the first 2 weeks' worth of daily ratings, participants will be
      assigned randomly to receive treatment with relaxation and self-control desensitization, CBT,
      or a combination of the two treatments. All participants will receive 14 weekly treatment
      sessions lasting between 1.5 and 2 hours each. During CBT sessions, participants will learn
      to identify ways in which they perceive themselves and the world and how to modify these
      thoughts to reduce anxiety. Applied relaxation and self-control desensitization sessions will
      teach participants relaxation techniques and the use of imagery for coping with anxiety.
      Between sessions, all participants will complete homework assignments that will involve
      practicing the approaches learned in sessions and continuing the daily diaries.

      Upon completion of treatment, participants will repeat the initial assessments. Follow-up
      visits will occur at Months 6, 12, and 24 after treatment completion and will include repeat
      interview and self-report sessions and completion of 1 week's worth of daily diary entries
      before each visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1991</start_date>
  <completion_date type="Actual">October 1998</completion_date>
  <primary_completion_date type="Actual">October 1998</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>High End State Function</measure>
    <time_frame>10-14 days after last therapy session and months 6, 12, and 24 following last therapy session</time_frame>
    <description>Percentage of participants meeting high end state functioning (e.g., within 1 standard deviation of mean of nonanxious samples on Hamilton Anxiety Rating Scales, Spielberger's State-Trait Anxiety Inventory, Penn State Worry Questionnaire, and Reactions to Relaxation and Arousal Questionnaire)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Within-group Change Represented as Cohen's d Effect Sizes</measure>
    <time_frame>10-14 days after last therapy session and months 6, 12, and 24 following last therapy session</time_frame>
    <description>Cohen's d within-group effect sizes comparing pre-therapy assessment to assessment at 10-14 days after last therapy session, at 6-month follow-up, at 12-month follow-up, and at 24-month follow-up. Findings reported in table are Cohen's d effect sizes averaged over Hamilton Anxiety Scale (scores ranging from 0-56, higher scores mean more anxiety), the Assessor Severity Scale (scores ranging from 0-8, higher scores mean more severity), and the State-Trait Anxiety Inventory-Trait version (scores ranging from 20-80, higher scores mean more state anxiety). The within-group effective sizes are the posttherapy [or follow-up] mean minus pretherapy mean divided by the pretherapy standard deviation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Purely Behavioral therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive treatment with progressive and applied relaxation and self-control desensitization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognitive-Behavioral Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive treatment with cognitive therapy, progressive and applied relaxation, and self-control desensitization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognitive Therapy (CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive purely cognitive therapy including identification of maladaptive thought processes and training in cognitive restructuring.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Applied relaxation and self-control desensitization</intervention_name>
    <description>Applied relaxation and self-control desensitization sessions will teach participants relaxation techniques and the use of imagery for coping with anxiety. Treatment will include 14 weekly sessions.</description>
    <arm_group_label>Purely Behavioral therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive therapy (CT)</intervention_name>
    <description>CT sessions will teach participants to identify ways in which they perceive themselves and the world and how to modify these thoughts to reduce anxiety. CT will include 14 weekly sessions.</description>
    <arm_group_label>Cognitive Therapy (CT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive-Behavioral Therapy</intervention_name>
    <description>Includes all of the techniques in the other 2 interventions.</description>
    <arm_group_label>Cognitive-Behavioral Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary diagnosis of GAD

        Exclusion Criteria:

          -  Diagnosis of any of the following: panic disorder, subclinical GAD, severe depression,
             psychosis, or organic brain syndrome

          -  Currently receiving therapy for GAD or has previously received CBT

          -  Medical contributions to anxiety

          -  Currently taking antidepressant medication

          -  Current substance abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle G. Newman, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas D. Borkovec, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State University</name>
      <address>
        <city>University Park</city>
        <state>Pennsylvania</state>
        <zip>16802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Roemer L, Molina S, Borkovec TD. An investigation of worry content among generally anxious individuals. J Nerv Ment Dis. 1997 May;185(5):314-9.</citation>
    <PMID>9171808</PMID>
  </reference>
  <reference>
    <citation>Roemer L, Molina S, Litz BT, Borkovec TD. Preliminary investigation of the role of previous exposure to potentially traumatizing events in generalized anxiety disorder. Depress Anxiety. 1996-1997;4(3):134-8.</citation>
    <PMID>9166642</PMID>
  </reference>
  <reference>
    <citation>Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry. 2000 Jun;31(2):73-86.</citation>
    <PMID>11132119</PMID>
  </reference>
  <reference>
    <citation>Schut AJ, Castonguay LG, Borkovec TD. Compulsive checking behaviors in generalized anxiety disorder. J Clin Psychol. 2001 Jun;57(6):705-15.</citation>
    <PMID>11344459</PMID>
  </reference>
  <reference>
    <citation>Stöber, J., &amp; Borkovec, T. D. (2002). Reduced concreteness of worry in generalized anxiety disorder: Findings from a therapy study. Cognitive Therapy and Research, 26, 89-96.</citation>
  </reference>
  <reference>
    <citation>Behar E, Alcaine O, Zuellig AR, Borkovec TD. Screening for generalized anxiety disorder using the Penn State Worry Questionnaire: a receiver operating characteristic analysis. J Behav Ther Exp Psychiatry. 2003 Mar;34(1):25-43.</citation>
    <PMID>12763391</PMID>
  </reference>
  <reference>
    <citation>McLaughlin KA, Behar E, Borkovec TD. Family history of psychological problems in generalized anxiety disorder. J Clin Psychol. 2008 Jul;64(7):905-18. doi: 10.1002/jclp.20497.</citation>
    <PMID>18509873</PMID>
  </reference>
  <reference>
    <citation>Cassidy J, Lichtenstein-Phelps J, Sibrava NJ, Thomas CL Jr, Borkovec TD. Generalized anxiety disorder: connections with self-reported attachment. Behav Ther. 2009 Mar;40(1):23-38. doi: 10.1016/j.beth.2007.12.004. Epub 2008 Jun 24.</citation>
    <PMID>19187814</PMID>
  </reference>
  <reference>
    <citation>Newman MG, Przeworski A, Fisher AJ, Borkovec TD. Diagnostic comorbidity in adults with generalized anxiety disorder: impact of comorbidity on psychotherapy outcome and impact of psychotherapy on comorbid diagnoses. Behav Ther. 2010 Mar;41(1):59-72. doi: 10.1016/j.beth.2008.12.005. Epub 2009 Jun 8.</citation>
    <PMID>20171328</PMID>
  </reference>
  <reference>
    <citation>Newman MG, Fisher AJ. Expectancy/Credibility Change as a Mediator of Cognitive Behavioral Therapy for Generalized Anxiety Disorder: Mechanism of Action or Proxy for Symptom Change? Int J Cogn Ther. 2010 Sep;3:245-261.</citation>
    <PMID>21132075</PMID>
  </reference>
  <results_reference>
    <citation>Borkovec TD, Newman MG, Pincus AL, Lytle R. A component analysis of cognitive-behavioral therapy for generalized anxiety disorder and the role of interpersonal problems. J Consult Clin Psychol. 2002 Apr;70(2):288-98.</citation>
    <PMID>11952187</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2008</study_first_submitted>
  <study_first_submitted_qc>March 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2008</study_first_posted>
  <results_first_submitted>May 23, 2012</results_first_submitted>
  <results_first_submitted_qc>January 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2018</results_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Penn State University</investigator_affiliation>
    <investigator_full_name>Michelle G. Newman</investigator_full_name>
    <investigator_title>Study Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Summary data has been shared.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Principal diagnosis of GAD, no panic disorder, Clinician’s Severity Rating (CSR) for GAD of 4 or more, absence of concurrent therapy, no history of having received CBT methods in prior therapy, no medical contributions to the anxiety, no antidepressant medication, and absence of severe MDD, substance abuse, psychosis, and organic brain syndrome.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Self-control Desensitization</title>
          <description>Participants will receive treatment with applied relaxation and self-control desensitization.</description>
        </group>
        <group group_id="P2">
          <title>Cognitive Therapy</title>
          <description>Participants will receive treatment with cognitive therapy.</description>
        </group>
        <group group_id="P3">
          <title>Combined Cognitive Behavioral Therapy</title>
          <description>Participants will receive treatment with a combination of applied relaxation, self-control desensitization, and cognitive behavioral therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Self-control Desensitization</title>
          <description>Participants will receive treatment with applied relaxation and self-control desensitization.</description>
        </group>
        <group group_id="B2">
          <title>Cognitive Therapy</title>
          <description>Participants will receive treatment with cognitive therapy.</description>
        </group>
        <group group_id="B3">
          <title>Combined Cognitive Behavioral Therapy</title>
          <description>Participants will receive treatment with a combination of applied relaxation, self-control desensitization, and cognitive behavioral therapy.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.02" spread="10.36"/>
                    <measurement group_id="B2" value="38.42" spread="11.10"/>
                    <measurement group_id="B3" value="35.64" spread="13.92"/>
                    <measurement group_id="B4" value="37.36" spread="11.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>High End State Function</title>
        <description>Percentage of participants meeting high end state functioning (e.g., within 1 standard deviation of mean of nonanxious samples on Hamilton Anxiety Rating Scales, Spielberger's State-Trait Anxiety Inventory, Penn State Worry Questionnaire, and Reactions to Relaxation and Arousal Questionnaire)</description>
        <time_frame>10-14 days after last therapy session and months 6, 12, and 24 following last therapy session</time_frame>
        <population>People who completed treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Self-control Desensitization</title>
            <description>Participants will receive treatment with applied relaxation and self-control desensitization.</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Therapy</title>
            <description>Participants will receive treatment with cognitive therapy.</description>
          </group>
          <group group_id="O3">
            <title>Combined Cognitive Behavioral Therapy</title>
            <description>Participants will receive treatment with a combination of applied relaxation, self-control desensitization, and cognitive behavioral therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>High End State Function</title>
          <description>Percentage of participants meeting high end state functioning (e.g., within 1 standard deviation of mean of nonanxious samples on Hamilton Anxiety Rating Scales, Spielberger's State-Trait Anxiety Inventory, Penn State Worry Questionnaire, and Reactions to Relaxation and Arousal Questionnaire)</description>
          <population>People who completed treatment</population>
          <units>% people meeting high endstate status</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10-14 days after last therapy session</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.52"/>
                    <measurement group_id="O2" value="43.48"/>
                    <measurement group_id="O3" value="56.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.62"/>
                    <measurement group_id="O2" value="68.18"/>
                    <measurement group_id="O3" value="56.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 month follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.57"/>
                    <measurement group_id="O2" value="47.62"/>
                    <measurement group_id="O3" value="43.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 month follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.62"/>
                    <measurement group_id="O2" value="52.38"/>
                    <measurement group_id="O3" value="38.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Within-group Change Represented as Cohen's d Effect Sizes</title>
        <description>Cohen's d within-group effect sizes comparing pre-therapy assessment to assessment at 10-14 days after last therapy session, at 6-month follow-up, at 12-month follow-up, and at 24-month follow-up. Findings reported in table are Cohen's d effect sizes averaged over Hamilton Anxiety Scale (scores ranging from 0-56, higher scores mean more anxiety), the Assessor Severity Scale (scores ranging from 0-8, higher scores mean more severity), and the State-Trait Anxiety Inventory-Trait version (scores ranging from 20-80, higher scores mean more state anxiety). The within-group effective sizes are the posttherapy [or follow-up] mean minus pretherapy mean divided by the pretherapy standard deviation.</description>
        <time_frame>10-14 days after last therapy session and months 6, 12, and 24 following last therapy session</time_frame>
        <population>People who completed treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Self-control Desensitization</title>
            <description>Participants will receive treatment with applied relaxation and self-control desensitization.</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Therapy</title>
            <description>Participants will receive treatment with cognitive therapy.</description>
          </group>
          <group group_id="O3">
            <title>Combined Cognitive Behavioral Therapy</title>
            <description>Participants will receive treatment with a combination of applied relaxation, self-control desensitization, and cognitive behavioral therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Within-group Change Represented as Cohen's d Effect Sizes</title>
          <description>Cohen's d within-group effect sizes comparing pre-therapy assessment to assessment at 10-14 days after last therapy session, at 6-month follow-up, at 12-month follow-up, and at 24-month follow-up. Findings reported in table are Cohen's d effect sizes averaged over Hamilton Anxiety Scale (scores ranging from 0-56, higher scores mean more anxiety), the Assessor Severity Scale (scores ranging from 0-8, higher scores mean more severity), and the State-Trait Anxiety Inventory-Trait version (scores ranging from 20-80, higher scores mean more state anxiety). The within-group effective sizes are the posttherapy [or follow-up] mean minus pretherapy mean divided by the pretherapy standard deviation.</description>
          <population>People who completed treatment</population>
          <units>Cohen's d within group effect size</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10-14 days after last therapy session</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38"/>
                    <measurement group_id="O2" value="2.95"/>
                    <measurement group_id="O3" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35"/>
                    <measurement group_id="O2" value="2.81"/>
                    <measurement group_id="O3" value="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 month year follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.43"/>
                    <measurement group_id="O2" value="2.48"/>
                    <measurement group_id="O3" value="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 month follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34"/>
                    <measurement group_id="O2" value="2.67"/>
                    <measurement group_id="O3" value="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Self-control Desensitization</title>
          <description>Participants will receive treatment with applied relaxation and self-control desensitization.</description>
        </group>
        <group group_id="E2">
          <title>Cognitive Therapy</title>
          <description>Participants will receive treatment with cognitive therapy.</description>
        </group>
        <group group_id="E3">
          <title>Combined Cognitive Behavioral Therapy</title>
          <description>Participants will receive treatment with a combination of applied relaxation, self-control desensitization, and cognitive behavioral therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michelle G. Newman</name_or_title>
      <organization>Penn State University</organization>
      <phone>814-863-1148</phone>
      <email>mgn1@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

